A detailed history of Sg Americas Securities, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 1,561 shares of BGNE stock, worth $313,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,561
Previous 467 234.26%
Holding current value
$313,745
Previous $105,000 174.29%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$174.72 - $246.04 $191,143 - $269,167
1,094 Added 234.26%
1,561 $288,000
Q3 2024

Oct 03, 2024

BUY
$143.93 - $224.51 $67,215 - $104,846
467 New
467 $105,000
Q4 2023

Jan 12, 2024

SELL
$158.67 - $201.58 $26,656 - $33,865
-168 Reduced 19.4%
698 $126,000
Q3 2023

Oct 13, 2023

SELL
$179.87 - $225.13 $5.31 Million - $6.64 Million
-29,501 Reduced 97.15%
866 $156,000
Q2 2023

Jul 10, 2023

SELL
$178.3 - $266.78 $424,532 - $635,203
-2,381 Reduced 7.27%
30,367 $5.41 Million
Q1 2023

Apr 28, 2023

BUY
$215.53 - $274.5 $2.69 Million - $3.43 Million
12,500 Added 61.73%
32,748 $7.06 Million
Q4 2022

Feb 02, 2023

BUY
$125.51 - $229.3 $2.54 Million - $4.64 Million
20,248 New
20,248 $4.45 Million
Q2 2022

Jul 29, 2022

SELL
$121.11 - $216.05 $3.8 Million - $6.79 Million
-31,416 Reduced 94.65%
1,776 $287,000
Q1 2022

Apr 29, 2022

SELL
$146.52 - $269.56 $127,472 - $234,517
-870 Reduced 2.55%
33,192 $6.26 Million
Q4 2021

Feb 07, 2022

BUY
$248.56 - $389.34 $2.15 Million - $3.37 Million
8,655 Added 34.07%
34,062 $9.23 Million
Q3 2021

Nov 01, 2021

SELL
$249.6 - $403.14 $1.42 Million - $2.29 Million
-5,689 Reduced 18.29%
25,407 $9.22 Million
Q2 2021

Aug 12, 2021

BUY
$292.75 - $367.01 $4.81 Million - $6.04 Million
16,446 Added 112.26%
31,096 $10.7 Million
Q1 2021

May 13, 2021

SELL
$260.64 - $382.12 $5.55 Million - $8.14 Million
-21,298 Reduced 59.25%
14,650 $5.1 Million
Q4 2020

Feb 04, 2021

BUY
$221.31 - $316.61 $6.28 Million - $8.99 Million
28,384 Added 375.25%
35,948 $9.29 Million
Q3 2020

Nov 09, 2020

BUY
$189.18 - $286.44 $787,745 - $1.19 Million
4,164 Added 122.47%
7,564 $2.17 Million
Q2 2020

Jul 20, 2020

BUY
$123.9 - $195.41 $83,880 - $132,292
677 Added 24.86%
3,400 $641,000
Q1 2020

Apr 30, 2020

BUY
$121.84 - $173.19 $331,770 - $471,596
2,723 New
2,723 $335,000
Q4 2019

Jan 28, 2020

SELL
$115.78 - $208.34 $1.57 Million - $2.82 Million
-13,540 Closed
0 $0
Q3 2019

Nov 04, 2019

BUY
$120.61 - $148.29 $1.63 Million - $2.01 Million
13,540 New
13,540 $1.66 Million
Q1 2019

Apr 29, 2019

SELL
$122.82 - $151.83 $314,787 - $389,140
-2,563 Closed
0 $0
Q4 2018

Feb 01, 2019

BUY
$107.01 - $175.15 $274,266 - $448,909
2,563 New
2,563 $359,000
Q2 2018

Aug 07, 2018

SELL
$152.5 - $216.77 $421,510 - $599,152
-2,764 Closed
0 $0
Q1 2018

May 03, 2018

SELL
$97.41 - $177.22 $202,612 - $368,617
-2,080 Reduced 42.94%
2,764 $464,000
Q4 2017

Jan 24, 2018

SELL
$79.6 - $114.73 $99,818 - $143,871
-1,254 Reduced 20.56%
4,844 $473,000
Q3 2017

Nov 07, 2017

BUY
$66.19 - $103.46 $403,626 - $630,899
6,098
6,098 $631,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.